Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Cathinone

or Research material

or potent non-selective)]]

Use the filters below to narrow your results.

Other values:

None (130) · (none, never marketed) (1) · Indocin (oral, IV, suppository), Tivorbex (low-dose), Indo-Lemmon (1) · O-DSMT (1)

5-HT2A agonist (26) · Monoamine releasing agent (9) · GABAA positive allosteric modulator (8) · CB1/CB2 agonist (7) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Serotonin/norepinephrine/dopamine releasing agent (3) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist (2) · Prodrug of GHB (2)

Other values:

None (131) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1)

None (131) · Acute gout: 50 mg PO TID until symptom relief, then taper; maximum 200 mg/day for 3-5 days. Rheumatoid arthritis / osteoarthritis: 25-50 mg PO BID-TID. Patent ductus arteriosus: 0.2 mg/kg IV, then 0.1-0.2 mg/kg every 12-24 hours for 2 doses (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)

None (131) · Capsules 25, 50 mg; ER capsules 75 mg; oral suspension 25 mg/5 mL; suppositories 50 mg; injection 1 mg/vial (PDA closure) (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)

None (131) · 200 mg/day (typical adult oral) (1) · N/A (never approved) (1)

None (131) · intranasal; rectal and IV reported. (1) · intravenous (PDA closure only) (1) · Oral (2) · rectal (1) · sublingual (1)

None (131) · 30-60 minutes (oral); rapid relief in acute gout (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (131) · 4-6 hours (IR); 24 hours (ER) (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1)

None (131) · 4-5 hours'"`UNIQ--ref-00000026-QINU`"' (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1)

None (131) · Not formally characterized in humans. (1) · ~100% (oral)'"`UNIQ--ref-00000027-QINU`"' (1)

None (131) · Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning; contraindicated from 30 weeks (risk of premature ductus arteriosus closure, which is paradoxically the basis of the neonatal PDA-closure indication)'"`UNIQ--ref-00000028-QINU`"' (1) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1)

None (132) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 147 results in range #1 to #147.

1

2

3

4

5

A

B

C

D

E

F

G

GBL

H

I

J

L

LSH
LSZ

M

N

O

P

R

RTI-111

S

STS-135

T

U

U-47700

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"